VolitionRx Limited - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
VNRX NYSE American 3840 www.volition.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for VolitionRx Limited

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation - Jul 16th, 2025 6:00 am
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - Jul 8th, 2025 6:00 am
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure - Jun 12th, 2025 6:30 am
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Jun 4th, 2025 7:00 pm
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis. - May 27th, 2025 6:07 am
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - May 19th, 2025 6:30 am
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - May 17th, 2025 1:02 am
VolitionRX: Q1 Earnings Snapshot - May 15th, 2025 4:12 pm
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update - May 15th, 2025 3:37 pm
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - May 12th, 2025 6:30 am
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - May 7th, 2025 6:30 am
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Apr 29th, 2025 6:30 am
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Apr 1st, 2025 1:03 am
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Mar 31st, 2025 2:05 pm
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 - Mar 28th, 2025 6:00 am
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - Mar 27th, 2025 6:30 am
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Mar 26th, 2025 6:00 am
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Mar 25th, 2025 7:30 am
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Mar 21st, 2025 6:30 am
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Mar 20th, 2025 6:30 am